Cargando…
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study
Patients with relapsed warm antibody autoimmune hemolytic anemia (wAIHA) have limited treatment options. Fostamatinib is a potent, orally administered spleen tyrosine kinase inhibitor approved in the United States and Europe for the treatment of adults with chronic immune thrombocytopenia (ITP). Thi...
Autores principales: | Kuter, David J., Rogers, Kerry A., Boxer, Michael A., Choi, Michael, Agajanian, Richy, Arnold, Donald M., Broome, Catherine M., Field, Joshua J., Murakhovskaya, Irina, Numerof, Robert, Tong, Sandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313871/ https://www.ncbi.nlm.nih.gov/pubmed/35179251 http://dx.doi.org/10.1002/ajh.26508 |
Ejemplares similares
-
Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia
por: Murakhovskaya, Irina
Publicado: (2020) -
Development of New Drugs for Autoimmune Hemolytic Anemia
por: Xiao, Zhengrui, et al.
Publicado: (2022) -
Autoimmune hemolytic anemia during pregnancy and puerperium: an international multicenter experience
por: Fattizzo, Bruno, et al.
Publicado: (2023) -
Immunotherapy Treatments of Warm Autoimmune Hemolytic Anemia
por: Liu, Bainan, et al.
Publicado: (2013) -
Educational Case: Warm Autoimmune Hemolytic Anemia
por: Arays, Ruta, et al.
Publicado: (2020)